Back to Search
Start Over
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
- Source :
-
Journal of Neurology . Jul2024, Vol. 271 Issue 7, p4655-4659. 5p. - Publication Year :
- 2024
-
Abstract
- This article discusses a case report on the use of bispecific CAR-T cell therapy in a patient with refractory myasthenia gravis (MG), an autoimmune neuromuscular disorder. The patient experienced sustained disappearance of symptoms and anti-acetylcholine receptor antibodies after receiving the therapy. The study suggests that bispecific CAR-T cell therapy has the potential to be an effective treatment for MG and other diseases characterized by autoreactive B cells and autoantibodies. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 03405354
- Volume :
- 271
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Journal of Neurology
- Publication Type :
- Academic Journal
- Accession number :
- 178340963
- Full Text :
- https://doi.org/10.1007/s00415-024-12367-4